Rassohin V.V., Buzunova S.A., Vrackih T.V., Panteleeva O.V., Toropov S.E., Totrova Z.M., Golubkin A.A., Orlov G.M., Belyakov N.A. [The problem of senescence and debilitation of HIV patients]. HIV Infection and Immunosuppressive Disorders 2015; 7 (1): 7–15. (In Russ.). doi.org/10.22328/ 2077-9828-2015-7-1-7-15

2. Эпидситуация по ВИЧ-инфекции в Республике Беларусь по состоянию на 01.04.2021. http://cgeud.by/2021/04/14

[Epidsituation on HIV infection in the Republic of Belarus as of 01.04.2021]. (In Russ.). http://cgeud.by/2021/04/14

3. Матиевская Н.В., Кашевник Т.И., Кратков О.В. ВИЧ-инфекция у пациентов пожилого возраста: клинические случаи. Актуальна инфектологiя 2020; 8(1): 45–9. DOI: 10.22141/2312-413x.8.1.2020.196171

Matievskaya N.V., Kashevnik T.I., Kratkov O.V. [HIV infection in elderly patients: clinical cases]. Aktual’na infektologiya 8(1): 45–9. (In Russ.). DOI:10.22141/2312-413x.8.1.2020.196171.

4. Беляева В.В., Козырина Н.В., Куимова У.А., Голиусова М.Д., Ефремова О.С. Профилактика передачи ВИЧ в дискордантных парах: информированность, осознание риска, поведение. Инфекционные болезни 2021; 10(1): 46–51. DOI: 10.33029/2305-3496-2021-10-1-46-51

Belyaeva V.V., Kozyrina N.V., Kuimova U.A., Goliusova M.D., Efremova O.S. [Prevention of HIV transmission in discordant couples: awareness, risk awareness, behavior]. Infectious Diseases 2021; 10(1): 46–51. (In Russ.). DOI: 10.33029/2305-3496-2021-10-1-46-51

5. World Health Organization (WHO) HIV/AID Ssection] .https://www.who. int/news-room/fact-sheets/detail/hiv-aids.

6. Матиевская Н.В., Кашевник Т.И., Казыро Л.М. Гендерные и возрастные особенности течения ВИЧ-инфекции. Клиническая инфектология и паразитология 2018; 7(4): 498–507.

Matievskaya N.V., Kashevnik T.I., Kazyro L.M [Gender and age characteristics of the course of HIV infection]. Clinical infectology and parasitology 2018; 7(4): 498–507. (In Russ.).

7. Gantner P., Cuzin L., Allavena C., Cabie A., Pugliese P., Valantin M-A. et al. Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study. HIV Med. 2017; 18: 704–708. doi: 10.1111/hiv.12506

8. Llibre J.M., Hung C.C., Brinson C., Castelli F., Girard P.-M., Kahl L.P. et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet 2018; 391: 839–49. DOI:10.1016/S0140-6736(17)33095-7

9. Taiwo B.O., Marconi V.C., Berzins B., Moser C.B.., Nyaku A.N., Fichtenbaum C.J., Benson. et al. Dolutegravir plus lamivudine maintains human immunodeficiency virus-1 suppression through week 48 in a pilot ran- domized trial. Clin. Infect. Dis. 2018; 66: 1794–7. doi: 10.1093/cid/cix1131

10. Cahn P., Madero J.S., Arribas J.R., Antinori A., Ortiz R., Clarke A.E. et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovirdisoproxilfumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet 2019; 393: 143–55. doi: 10.1016/S0140-6736(18)32462-0

11. US Department of Health and Human Services. Guidelines for the use of anti-retroviral agents in adults and adolescents living with HIV. https://aidsinfo.nih.gov/guidelines

12. European AIDS Clinical Society. EACS treatment guidelines 10.0. http://www.eacsociety.org/

13. Покровский В.В., Юрин О.Г., Кравченко А.В., Беляева В.В., Ермак Т.Н., Канестри В.Г. и др. Рекомендации по лечению ВИЧ-инфекции и связанных с ней заболеваний, химиопрофилактике заражения ВИЧ. Эпидемиол. инфекц. болезни. Актуал. вопр. 2019; 9(4, приложение). http://www.hivrussia.info/metodicheskie-rekomendatsii-i-protokoly/

Pokrovsky V.V., Yurin O.G., Kravchenko A.V., Belyaeva V.V., Ermak T.N., Kanestri V.G. et al. [Recommendations for the treatment of HIV infection and related diseases, chemoprophylaxis of HIV infection]. Epidemiligy and infectious diseases. Current items 2019; (4, Suppl.). (In Russ.). http://www.hivrussia. info/metodicheskie-rekomendatsii-i-protokoly/

14. Li L., He H., Lan Y., Chen J., Zhong H., Nie J. et al. Dual Therapy with Lopinavir/Ritonavir plus Lamivudine could be a Viable Alternative for Antiretroviral‑Therapy‑Naive Adults with HIV‑1 Infection Regardless of HIV Viral Load or Subgenotype in Resource‑Limited Settings: A Randomised, Open‑Label and Non‑Inferiority Study from China. Indian J. Med. Microbiol. 2018; 36(4): 513–16. doi: 10.4103/ijmm.IJMM_18_172

15. Cahn P., Andrade-Villanueva J., Arribas J.R., Gatell J.M., Lama J.R., Norton M. et al. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet Infect. Dis. 2014; 14(7): 572–80. DOI: 10.1016/ S1473-3099(14)70736-4

16. Матиевская Н.В. Антиретровирусная терапия ВИЧ-инфекции: перспективы упрощения схем. ВИЧ-инфекция и иммуносупрессии 2017; 9(2): 27–35. doi.org/10.22328/2077-9828-2017-9-2-27-35

Matievskaya N.V. [Antiretroviral therapy for HIV infection: prospects for simplification of regimens]. HIV Infection and Immunosuppressive Disorders 2017; 9(2): 27–35. (In Russ.). doi.org/10.22328/2077-9828-2017-9-2-27-35